Table 3. Cox regression analyses assessing survival in patients with small-cell lung cancer who received chemoradiotherapy compared with those receiving chemotherapy alone.
| N | N who died | %a | Unadjusted HR (95% CI) | Adjusted HR (95% CI)b | P-value | |
|---|---|---|---|---|---|---|
| Whole cohort | 7782 | |||||
| CTx alone | 3914 | 3463 | 88 | <0.001 | ||
| CTx and RTx | 861 | 670 | 78 | 0.66 (0.61, 0.72) | 0.70 (0.65, 0.76) | |
| Limited stage | 1319 | |||||
| CTx alone | 737 | 594 | 81 | <0.001 | ||
| CTx and RTx | 280 | 184 | 66 | 0.69 (0.58, 0.81) | 0.72 (0.62, 0.84) |
Abbreviations: CI=confidence interval; CTx=chemotherapy; HR=hazard ratio; N=number; NHS=National Health Service; RTx=radiotherapy.
a
Percentage of patients who died.
b
HR adjusted for sex, age, performance status, stage (whole cohort only), Townsend quintile, ethnic group and Charlson index. Clustered on NHS Trust.
Some patients had no record of any treatment received, and some received surgery, whereas others received radiotherapy alone.
Whole cohort; no treatment, N=2360; surgery, N=148; and radiotherapy alone, N=499.
Limited stage only: no treatment, N=218; surgery, N=20; and radiotherapy alone, N=64.